Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion

TY - JOUR

T1 - Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion

AU - Brimnes, Marie Klinge

AU - Gang, Anne Ortved

AU - Donia, Marco

AU - Thor Straten, Per

AU - Svane, Inge Marie

AU - Hadrup, Sine Reker

PY - 2012/8

Y1 - 2012/8

N2 - Adoptive cell transfer (ACT) of in vitro expanded autologous tumor-inWltrating lymphocytes (TIL) has been shown to exert therapeutic eYcacy in melanoma patients. We aimed to develop an ACT protocol based on tumor-speciWc T cells isolated from peripheral blood and in vitro expanded by Dynabeads® ClinExVivo™CD3/CD28. We show here that the addition of an in vitro restimulation step with relevant peptides prior to bead expansion dramatically increased the proportion of tumor-speciWc T cells in PBMC-cultures. Importantly, peptide-pulsed dendritic cells (DCs) as well as allogeneic tumor lysate-pulsed DCs from the DC vaccine preparation could be used with comparable eYciency to peptides for in vitro restimulation, to increase the tumor-speciWc T-cell response. Furthermore, we tested the use of diVerent ratios and diVerent types of Dynabeads® CD3/CD28 and CD3/CD28/CD137 T-cell expander, for optimized expansion of tumor-speciWc T cells. A ratio of 1:3 of Dynabeads® CD3/CD28 T-cell expander to T cells resulted in the maximum number of tumor-speciWc T cells. The addition of CD137 did not improve functionality or fold expansion. Both T-cell expansion systems could generate tumor-speciWc T cells that were both cytotoxic and eVective cytokine producers upon antigen recognition. Dynabeads®- expanded T-cell cultures shows phenotypical characteristics of memory T cells with potential to migrate and expand in vivo. In addition, they possess longer telomeres compared to TIL cultures. Taken together, we demonstrate that in vitro restimulation of tumor-speciWc T cells prior to bead expansion is necessary to achieve high numbers of tumor-speciWc T cells. This is eVective and easily applicable in combination with DC vaccination, by use of vaccine-generated DCs, either pulsed with peptide or tumor-lysate.

AB - Adoptive cell transfer (ACT) of in vitro expanded autologous tumor-inWltrating lymphocytes (TIL) has been shown to exert therapeutic eYcacy in melanoma patients. We aimed to develop an ACT protocol based on tumor-speciWc T cells isolated from peripheral blood and in vitro expanded by Dynabeads® ClinExVivo™CD3/CD28. We show here that the addition of an in vitro restimulation step with relevant peptides prior to bead expansion dramatically increased the proportion of tumor-speciWc T cells in PBMC-cultures. Importantly, peptide-pulsed dendritic cells (DCs) as well as allogeneic tumor lysate-pulsed DCs from the DC vaccine preparation could be used with comparable eYciency to peptides for in vitro restimulation, to increase the tumor-speciWc T-cell response. Furthermore, we tested the use of diVerent ratios and diVerent types of Dynabeads® CD3/CD28 and CD3/CD28/CD137 T-cell expander, for optimized expansion of tumor-speciWc T cells. A ratio of 1:3 of Dynabeads® CD3/CD28 T-cell expander to T cells resulted in the maximum number of tumor-speciWc T cells. The addition of CD137 did not improve functionality or fold expansion. Both T-cell expansion systems could generate tumor-speciWc T cells that were both cytotoxic and eVective cytokine producers upon antigen recognition. Dynabeads®- expanded T-cell cultures shows phenotypical characteristics of memory T cells with potential to migrate and expand in vivo. In addition, they possess longer telomeres compared to TIL cultures. Taken together, we demonstrate that in vitro restimulation of tumor-speciWc T cells prior to bead expansion is necessary to achieve high numbers of tumor-speciWc T cells. This is eVective and easily applicable in combination with DC vaccination, by use of vaccine-generated DCs, either pulsed with peptide or tumor-lysate.

U2 - 10.1007/s00262-011-1199-8

DO - 10.1007/s00262-011-1199-8

M3 - Journal article

C2 - 22237888

SN - 0340-7004

VL - 61

SP - 1221

EP - 1231

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 8

ER -